sarepta therapeutics arrowhead news - Search News

Arrowhead climbs

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta Therapeutics. TransMedics Group's (NASDAQ:TMDX) investors will be pleased with their massive 349% return over the last five years The Stock ...

YAHOO!Finance · 2h

Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments

Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and collaboration agreement with Arrowhead (ARWR) Pharmaceuticals ( ARWR).

Seeking Alpha on MSN · 1d

Arrowhead climbs after licensing deal with Sarepta

Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ:SRPT) for various clinical and preclinical programs.

Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases

Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...

16h

Sarepta Therapeutics’ Strategic Partnership with Arrowhead Signals Strong Growth Prospects: A Buy Recommendation

Analyst Kostas Biliouris of BMO Capital reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

21h

Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Rx Rundown: Roche, Sarepta Therapeutics, Merck and more

Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results